-
July 16, 2026
Starship Flight 13: First Post-IPO Integrated Test Flight
Starbase, Texas — SpaceX is scheduled to conduct Starship's 13th integrated flight test, the first since the company's June IPO. The mission will test booster catch, ship reentry, and payload deployment systems critical to Mars architecture.
-
July 15, 2026
SpaceX Shares Trade Below IPO Price for First Time
SPCX closed at $135.27 after reaching an intraday low of $132.15, marking the first session below the $135 offer price. The stock has declined from a mid-June peak of $225.64 as investors reassess AI spending and lock-up expiries.
-
June 23, 2026
SpaceX Announces Pricing of $25 Billion Inaugural Bond Issuance
Starbase, Texas — SpaceX (Nasdaq: SPCX) announced pricing of $7.0 billion of 5.350% Senior Notes due 2031, $6.0 billion of 5.650% Senior Notes due 2033, and $6.0 billion of 5.900% Senior Notes due 2036.
-
June 15, 2026
SpaceX Announces Closing of Initial Public Offering
STARBASE, Texas — SpaceX closed its IPO of 638,888,888 Class A shares at $135.00, including full exercise of the underwriters' overallotment option. Gross proceeds: approximately $85.7 billion. Trading began June 12 under ticker SPCX.
-
June 12, 2026
SpaceX Announces Pricing of Initial Public Offering at $135/Share
STARBASE, Texas — SpaceX confirmed pricing of 555,555,555 shares of Class A common stock at $135.00 per share. Shares began trading on Nasdaq Global Select Market and Nasdaq Texas under symbol "SPCX."
-
June 4, 2026
SpaceX Announces Launch of Initial Public Offering Roadshow
STARBASE, Texas — SpaceX launched the roadshow for its IPO of 555,555,555 shares of Class A common stock, with a 30-day underwriter option for an additional 83,333,333 shares.
-
May 2026
xAI Completes Integration of Grok 4 Architecture
xAI advances Grok's real-time reasoning capabilities, deploying across X platform and enterprise APIs. SpaceX Q1 2026 capex allocated $7.7B to AI segment including xAI and Cursor acquisition.
-
January 2024
Neuralink Receives FDA Approval for First Human Clinical Trial
Neuralink's PRIME Study received FDA Breakthrough Device designation, enabling implantation of N1 chip in patients with quadriplegia. First patient received implant January 2024.
-
October 2022
Elon Musk Completes Acquisition of Twitter, Rebrands to X
Musk closed the $44 billion acquisition of Twitter Inc., taking the company private. Rebranding to X begins the transformation into an "everything app" integrating payments, media, and AI.
-
July 2023
xAI Founded to Understand the True Nature of the Universe
Musk announces xAI, assembling researchers from DeepMind, OpenAI, Google, and Tesla to build advanced AI systems with emphasis on truth-seeking and scientific understanding.